摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-3-氟苯甲酸甲酯 | 647020-70-0

中文名称
2-氯-3-氟苯甲酸甲酯
中文别名
——
英文名称
methyl 2-chloro-3-fluorobenzoate
英文别名
——
2-氯-3-氟苯甲酸甲酯化学式
CAS
647020-70-0
化学式
C8H6ClFO2
mdl
——
分子量
188.586
InChiKey
NRTGZMADMOJUAV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-3-氟苯甲酸甲酯硫酸三甲基铝硝酸铁粉氯化铵 作用下, 以 乙醇甲苯 为溶剂, 反应 5.2h, 生成 5-amino-2-chloro-N-(3-chloro-5-methyl-phenyl)-3-fluoro-benzamide
    参考文献:
    名称:
    [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    摘要:
    在这里,描述了用于调节与神经退行性疾病、肌肉骨骼疾病、癌症、眼科疾病和病毒感染相关的细胞中包涵体形成和应激颗粒的化合物、组合物和方法。
    公开号:
    WO2020117877A1
  • 作为产物:
    描述:
    甲醇2-氯-3-氟苯甲酸草酰氯N,N-二甲基甲酰胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 生成 2-氯-3-氟苯甲酸甲酯
    参考文献:
    名称:
    [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    摘要:
    在这里,描述了用于调节与神经退行性疾病、肌肉骨骼疾病、癌症、眼科疾病和病毒感染相关的细胞中包涵体形成和应激颗粒的化合物、组合物和方法。
    公开号:
    WO2020117877A1
点击查看最新优质反应信息

文献信息

  • Inhibitors of cyclin-dependent kinases and their use
    申请人:——
    公开号:US20040106581A1
    公开(公告)日:2004-06-03
    The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
    本发明涉及一种新型化合物,用于抑制细胞周期蛋白依赖性激酶,尤其是公式(Ia)的香豆素衍生物,其中R1、R2、R3、R4、R5、R6、R7和A的含义如权利要求中所示。本发明还涉及制备公式(Ia)化合物的方法,抑制细胞周期蛋白依赖性激酶和细胞增殖的方法,使用公式(Ia)化合物治疗和预防由于细胞周期蛋白依赖性激酶抑制而可以治疗或预防的疾病,如癌症,使用公式(Ia)化合物制备用于治疗此类疾病的药物。本发明还涉及含有公式(Ia)化合物的组合物,单独或与另一活性剂结合,与惰性载体混合或以其他方式结合,特别是含有公式(Ia)化合物的药物组合物,单独或与另一活性剂结合,与药用可接受载体物质和辅助物质一起使用的制剂。
  • INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE
    申请人:Lal Bansi
    公开号:US20070015802A1
    公开(公告)日:2007-01-18
    The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ic) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ic) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ic) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ic) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ic) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
    本发明涉及一种新型化合物,用于抑制细胞周期蛋白依赖性激酶,特别是公式(Ic)的香豆素衍生物,其中R1、R2、R3、R4、R5、R6、R7和A的含义如权利要求所示。本发明还涉及制备公式(Ia)化合物的方法,抑制细胞周期蛋白依赖性激酶和抑制细胞增殖的方法,以及使用公式(Ic)化合物在治疗和预防细胞周期蛋白依赖性激酶抑制剂可治疗或预防的疾病,如癌症,以及使用公式(Ic)化合物制备应用于这些疾病的药物。本发明还涉及含有公式(Ic)化合物的组合物,单独或与另一种活性剂联合使用,与惰性载体混合或以其他方式与惰性载体相结合,特别是含有公式(Ic)化合物的药物组合物,单独或与另一种活性剂联合使用,以及与药用载体物质和辅助物质相结合。
  • Inhibitors of Cyclin Dependent Kinases and Their Use
    申请人:Lal Bansi
    公开号:US20110136873A1
    公开(公告)日:2011-06-09
    The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
    本发明涉及新型化合物,用于抑制细胞周期蛋白依赖性激酶,更具体地说,涉及公式(Ia)的香豆酮衍生物,其中R1、R2、R3、R4、R5、R6、R7和A具有所述权利要求中指示的含义。本发明还涉及制备公式(Ia)化合物的方法,抑制细胞周期蛋白依赖性激酶和抑制细胞增殖的方法,以及使用公式(Ia)化合物治疗和预防通过抑制细胞周期蛋白依赖性激酶治疗或预防的疾病,如癌症,使用公式(Ia)化合物制备应用于此类疾病的药物。本发明还涉及含有公式(Ia)化合物的组合物,单独或与另一活性剂混合,与惰性载体混合或以其他方式与惰性载体相关联,特别是含有公式(Ia)化合物的制药组合物,单独或与另一活性剂混合,以及与药物可接受的载体物质和辅助物质一起使用。
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE
    申请人:Lal Bansi
    公开号:US20130045993A1
    公开(公告)日:2013-02-21
    The present invention relates to novel compounds for the inhibition of cyclindependent kinases, and more particularly, to chromenone derivatives of formula (Ia), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclindependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
    本发明涉及新型化合物,用于抑制细胞周期依赖性激酶,特别是公式(Ia)的香豆酮衍生物,其中R1、R2、R3、R4、R5、R6、R7和A具有所述权利要求中指定的含义。本发明还涉及制备公式(Ia)化合物的方法,抑制细胞周期依赖性激酶和抑制细胞增殖的方法,以及使用公式(Ia)化合物治疗和预防可通过抑制细胞周期依赖性激酶如癌症等疾病的用途,以及使用公式(Ia)化合物制备应用于此类疾病的药物。本发明还涉及含有公式(Ia)化合物的组合物,单独或与另一种活性剂混合,与惰性载体混合或以其他方式联合,特别是含有公式(Ia)化合物的药物组合物,单独或与另一种活性剂混合,以及与药用载体物质和辅助物质混合。
  • FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES
    申请人:Nicholas Piramal India Limited
    公开号:EP1556375A2
    公开(公告)日:2005-07-27
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐